Table 1.
Discovery cohort: clinical characteristics of patients with TLS-positive tumors (according to TLS status)
| Presence of TLS (n=105) |
No TLS (n=223) | |
|---|---|---|
| Median Age | 62 (range 35-84) | 62 (range 20-88) |
| Gender | ||
| Male | 57 (53%) | 139 (62%) |
| Female | 48 (47%) | 84 (38%) |
| Tumor Type | ||
| Non-small cell lung cancer | 37 (37.1%) | 90 (41.2%) |
| Soft-tissue sarcomas | 8 (7.6%) | 38 (17%) |
| Bladder cancer | 15 (14.3%) | 16 (7.2%) |
| Colorectal cancer | 11 (10.5%) | 16 (7%) |
| Head and neck carcinomas | 5 (4.8%) | 7 (3.1%) |
| Renal carcinoma | 2 (1.9%) | 8 (3.6%) |
| Breast carcinoma | 1 (1%) | 6 (2.7%) |
| Other | 26 (22.8%) | 42 (17.9%) |
| Performance status | ||
| ≤ 1 | 97 (92.4%) | 207 (92.8%) |
| > 1 | 8 (7.6%) | 16 (7.2%) |
| Previous lines of treatment | ||
| ≤ 1 | 65 (61.9%) | 138 (61.9%) |
| > 1 | 40 (38.1%) | 85 (38.1%) |
| Treatment | ||
| Anti-PD1 | 56 (53.3%) | 139 (62.3%) |
| Anti-PD-L1 | 38 (36.2%) | 62 (27.8%) |
| Combination PD1 or anti-PD-L1 + another immune checkpoint inhibitor | 11 (10.5%) | 22 (9.9%) |
*
Other tumors: thyroid carcinoma, gastrointestinal stromal tumor, cholangiocarcinoma, pancreatic adenocarcinoma, anal carcinoma, cervical cancer, ovarian cancer, vulvar carcinoma, endometrial carcinoma, cervical cancer, gastric carcinoma.